REVENUE (Tables)

3 Months Ended

Sep. 30, 2022

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the nine months ended September 30, 2022, is as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2021	$	21.5	$	13.9	$	0.7	$	36.1
Plus, credit loss expense	4.0		—		—		4.0
Less, write offs	(5.0)		(3.0)		(0.7)		(8.7)
Balance as of September 30, 2022	$	20.5	$	10.9	$	—	$	31.4

Contract with Customer, Asset and Liability [Table Text Block]

	September 30, 2022		December 31, 2021
Dx accounts receivable	$	1,051.1	$	1,193.8
DD accounts receivable	1,133.6		1,089.2
Less DD allowance for doubtful accounts	(20.5)		(21.5)
Accounts receivable	$	2,164.2	$	2,261.5
Gross unbilled services	$	829.4	$	730.8
Less reserve for unbilled services	(10.9)		(14.0)
Unbilled services	$	818.5	$	716.8
Unearned revenue	$	530.9	$	558.5

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three and nine months ended September 30, 2022, and 2021, were as follows:

	For the Three Months Ended September 30, 2022								For the Three Months Ended September 30, 2021
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	18	%	—	%	—	%	18	%	17	%	—	%	—	%	17	%
Patients	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Medicare and Medicaid	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Third party	31	%	—	%	—	%	31	%	35	%	—	%	—	%	35	%
Total Dx revenues by payer	61	%	—	%	—	%	61	%	64	%	—	%	—	%	64	%
DD
Pharmaceutical, biotechnology and medical device companies	19	%	12	%	8	%	39	%	22	%	10	%	4	%	36	%
Total revenues	80	%	12	%	8	%	100	%	86	%	10	%	4	%	100	%

	For the Nine Months Ended September 30, 2022								For the Nine Months Ended September 30, 2021
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	18	%	—	%	—	%	18	%	18	%	—	%	—	%	18	%
Patients	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Medicare and Medicaid	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Third party	31	%	—	%	—	%	31	%	34	%	—	%	—	%	34	%
Total Dx revenues by payer	61	%	—	%	—	%	61	%	64	%	—	%	—	%	64	%
DD
Pharmaceutical, biotechnology and medical device companies	19	%	13	%	7	%	39	%	22	%	10	%	4	%	36	%
Total revenues	80	%	13	%	7	%	100	%	86	%	10	%	4	%	100	%

Revenues in the U.S. were $2,791.8 (77.4%) and $3,352.7 (82.5%) for the three months ended September 30, 2022, and 2021, respectively, and for the nine months ended September 30, 2022, and 2021, were $8,649.3 (77.2%) and $9,926.7 (82.3%), respectively.

DD Contract costs

Capitalized Contract Cost [Table Text Block]

	September 30, 2022		December 31, 2021
Sales commission assets	$	38.9	$	36.2
Deferred contract fulfillment costs	15.7		14.4
Total	$	54.6	$	50.6